Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | CCR3 | P51677 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172121 | 0.93 | ABCB11 (0.61) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950574 | 0.90 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3145189 | 0.90 | ABCB11 (0.71) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3145179 | 0.90 | ABCB11 (0.71) | ABCB11LMNAMEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL3150804 | 0.87 | ABCB11 (0.65) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950573 | 0.87 | ABCB11 (0.60) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1950572 | 0.86 | ABCB11 (0.61) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1682971 | 0.85 | ABCB11 (0.64) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL1682972 | 0.85 | ABCB11 (0.64) | ABCB11LMNAMEN1KMT2AKDM4E | |
| SCHEMBL3145540 | 0.85 | ABCB11 (0.61) | ABCB11LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | ABCB11 1536/4885LMNA 2468/4885MEN1 4845/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | ABCB11 2075/4885LMNA 3129/4885MEN1 4750/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | ABCB11 1971/4885LMNA 3077/4885MEN1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.